open access

Ahead of print
Review Article
Published online: 2020-09-21
Get Citation

Small vessel coronary artery disease: How small can we go with myocardial revascularization?

Maciej T. Wybraniec, Paweł Bańka, Tomasz Bochenek, Tomasz Roleder, Katarzyna Mizia-Stec
DOI: 10.5603/CJ.a2020.0127
·
Pubmed: 32986235

open access

Ahead of print
Review articles
Published online: 2020-09-21

Abstract

The issue of small coronary artery atherosclerosis represents an intriguing aspect of coronary artery disease, which is related with higher rates of peri- and post-procedural complications and impaired long-term outcome. This problem is further complicated by the unclear definition of small coronary vessel. Recent randomized controlled trials have provided new data on possible novel interventional treatment of small coronary vessels with drug-coated balloons instead of traditional new-generation drug-eluting stent implantation. Also, the conservative management represents a therapeutic option in light of the results of the recent ISCHEMIA trial. The current article provides an overview of the most appropriate definition, interventional management, and prognosis of small coronary artery atherosclerosis.

Abstract

The issue of small coronary artery atherosclerosis represents an intriguing aspect of coronary artery disease, which is related with higher rates of peri- and post-procedural complications and impaired long-term outcome. This problem is further complicated by the unclear definition of small coronary vessel. Recent randomized controlled trials have provided new data on possible novel interventional treatment of small coronary vessels with drug-coated balloons instead of traditional new-generation drug-eluting stent implantation. Also, the conservative management represents a therapeutic option in light of the results of the recent ISCHEMIA trial. The current article provides an overview of the most appropriate definition, interventional management, and prognosis of small coronary artery atherosclerosis.

Get Citation

Keywords

small coronary artery disease, small coronary vessel, small vessel disease, drug-coated balloons, drug-eluting stents

About this article
Title

Small vessel coronary artery disease: How small can we go with myocardial revascularization?

Journal

Cardiology Journal

Issue

Ahead of print

Article type

Review Article

Published online

2020-09-21

DOI

10.5603/CJ.a2020.0127

Pubmed

32986235

Keywords

small coronary artery disease
small coronary vessel
small vessel disease
drug-coated balloons
drug-eluting stents

Authors

Maciej T. Wybraniec
Paweł Bańka
Tomasz Bochenek
Tomasz Roleder
Katarzyna Mizia-Stec

References (84)
  1. Biondi-Zoccai G, Sangiorgi G, Antoniucci D, et al. Testing prospectively the effectiveness and safety of paclitaxel-eluting stents in over 1000 very high-risk patients. Int J Cardiol. 2007; 117(3): 349–354.
  2. Akiyama T, Moussa I, Reimers B, et al. Angiographic and clinical outcome following coronary stenting of small vessels: a comparison with coronary stenting of large vessels. J Am Coll Cardiol. 1998; 32(6): 1610–1618.
  3. Scholz SS, Lauder L, Ewen S, et al. One-year clinical outcomes in patients with renal insufficiency after contemporary PCI: data from a multicenter registry. Clin Res Cardiol. 2020; 109(7): 845–856.
  4. Elezi S, Kastrati A, Neumann FJ, et al. Vessel Size and Long-Term Outcome After Coronary Stent Placement. Circulation. 1998; 98(18): 1875–1880.
  5. van der Heijden LC, Kok MM, Danse PW, et al. Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial. Am Heart J. 2016; 176: 28–35.
  6. Briguori C, Tobis J, Nishida T, et al. Discrepancy between angiography and intravascular ultrasound when analysing small coronary arteries. Eur Heart J. 2002; 23(3): 247–254.
  7. Biondi-Zoccai G, Moretti C, Abbate A, et al. Percutaneous coronary intervention for small vessel coronary artery disease. Cardiovasc Revasc Med. 2010; 11(3): 189–198.
  8. Dortimer AC, Shenoy PN, Shiroff RA, et al. Diffuse coronary artery disease in diabetic patients: fact or fiction? Circulation. 1978; 57(1): 133–136.
  9. Mosseri M, Yarom R, Gotsman MS, et al. Histologic evidence for small-vessel coronary artery disease in patients with angina pectoris and patent large coronary arteries. Circulation. 1986; 74(5): 964–972.
  10. Acharjee S, Teo KK, Jacobs AK, et al. COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007; 356(15): 1503–1516.
  11. Ong P, Safdar B, Seitz A, et al. Diagnosis of coronary microvascular dysfunction in the clinic. Cardiovasc Res. 2020; 116(4): 841–855.
  12. Ford TJ, Corcoran D, Berry C. Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need. Heart. 2018; 104(4): 284–292.
  13. Rogers JH, Lasala JM. Coronary artery dissection and perforation complicating percutaneous coronary intervention. J Invasive Cardiol. 2004; 16(9): 493–499.
  14. Ndrepepa G, Berger P, Mehilli J, et al. Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions. J Am Coll Cardiol. 2008; 51(7): 690–697.
  15. Rathore S, Terashima M, Katoh O, et al. Predictors of angiographic restenosis after drug eluting stents in the coronary arteries: contemporary practice in real world patients. EuroIntervention. 2009; 5(3): 349–354.
  16. Brodie B, Pokharel Y, Garg A, et al. Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction. JACC Cardiovasc Interv. 2012; 5(10): 1043–1051.
  17. Lee CH, Kang DY, Han M, et al. IRIS-DES Registry Investigators. Differential cutoff points and clinical impact of stent parameters of various drug-eluting stents for predicting major adverse clinical events: An individual patient data pooled analysis of seven stent-specific registries and 17,068 patients. Int J Cardiol. 2019; 282: 17–23.
  18. Agostoni P, Biondi-Zoccai GGL, Gasparini GL, et al. Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur Heart J. 2005; 26(9): 881–889.
  19. Jeger RV, Farah A, Ohlow MA, et al. BASKET-SMALL 2 Investigators. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. Lancet. 2018; 392(10150): 849–856.
  20. Doucet S, Schalij MJ, Vrolix MC, et al. Stent In Small Arteries(SISA) Trial Investigators. Stent placement to prevent restenosis after angioplasty in small coronary arteries. Circulation. 2001; 104(17): 2029–2033.
  21. Ardissino D, Cavallini C, Bramucci E, et al. Sirolimus-Eluting vs uncoated stents for prevention of restenosis in small coronary arteries. JAMA. 2004; 292(22): 2727.
  22. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40(2): 87–165.
  23. Knuuti J, Wijns W, Saraste A, et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41(3): 407–477.
  24. Hau WK. Fractional flow reserve and complex coronary pathologic conditions. Eur Heart J. 2004; 25(9): 723–727.
  25. Costa MA, Sabate M, Staico R, et al. Anatomical and physiologic assessments in patients with small coronary artery disease: final results of the Physiologic and Anatomical Evaluation Prior to and After Stent Implantation in Small Coronary Vessels (PHANTOM) trial. Am Heart J. 2007; 153(2): 296.e1–296.e7.
  26. Puymirat E, Peace A, Mangiacapra F, et al. Long-term clinical outcome after fractional flow reserve-guided percutaneous coronary revascularization in patients with small-vessel disease. Circ Cardiovasc Interv. 2012; 5(1): 62–68.
  27. Tu S, Westra J, Yang J, et al. Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve From Diagnostic Coronary Angiography. JACC: Cardiovascular Interventions. 2016; 9(19): 2024–2035.
  28. Erbay A, Steiner J, Lauten A, et al. Assessment of intermediate coronary lesions by fractional flow reserve and quantitative flow ratio in patients with small-vessel disease. Catheter Cardiovasc Interv. 2019 [Epub ahead of print].
  29. Zhuang B, Wang S, Zhao S, et al. Computed tomography angiography-derived fractional flow reserve (CT-FFR) for the detection of myocardial ischemia with invasive fractional flow reserve as reference: systematic review and meta-analysis. Eur Radiol. 2020; 30(2): 712–725.
  30. Li L, Wang Li, Zhai CJ, et al. Clinical utility of intravascular ultrasonography-guided therapy in a small-vessel coronary lesion associated with Type 2 diabetes mellitus. Anatol J Cardiol. 2019; 22(2): 68–76.
  31. Matsuo Y, Kubo T, Aoki H, et al. Optimal threshold of postintervention minimum stent area to predict in-stent restenosis in small coronary arteries: An optical coherence tomography analysis. Catheter Cardiovasc Interv. 2016; 87(1): E9–EE14.
  32. Kordish I, Philipp S, Boese D, et al. [Dissection of the right coronary artery as a complication after the IVUS procedure]. Herz. 2007; 32(7): 573–577.
  33. Judith S. Hochman at the American Heart Association Annual Scientific Sessions (AHA 2019). , Philadelphia, PA, November, 16, 2019.
  34. Jia H, Dai J, Hou J, et al. Effective anti-thrombotic therapy without stenting: intravascular optical coherence tomography-based management in plaque erosion (the EROSION study). Eur Heart J. 2017; 38(11): 792–800.
  35. Xing L, Yamamoto E, Sugiyama T, et al. EROSION Study (Effective Anti-Thrombotic Therapy Without Stenting: Intravascular Optical Coherence Tomography-Based Management in Plaque Erosion): A 1-Year Follow-Up Report. Circ Cardiovasc Interv. 2017; 10(12).
  36. Yano H, Horinaka S, Ishikawa M, et al. Efficacy of everolimus-eluting stent implantation in patients with small coronary arteries (≤2.5 mm): outcomes of 3-year clinical follow-up. Heart Vessels. 2017; 32(7): 796–803.
  37. https://www.bostonscientific.com/en-US/products/catheters--balloon/apex-ptca-dilatation-catheter.html (Date of entry: 30).
  38. https://www.medtronic.com/us-en/healthcare-professionals/products/cardiovascular/coronary-balloons/sprinter-legend-rx-semicompliant.html (Date of entry: 30).
  39. https://www.terumo-europe.com/en-emea/products/ryurei%E2%84%A2-ptca-dilatation-catheter (Date of entry: 30).
  40. https://www.orbusneich.com/en/products/semi-compliant-balloons/sapphire (Date of entry: 30).
  41. https://www.sis-medical.com/nic-nano-0-85-cto-balloon (Date of entry: 30).
  42. Lee P, Kwon O, Ahn JM, et al. Safety and effectiveness of second-generation drug-eluting stents in Patients with left main coronary artery disease. J Am Coll Cardiol. 2018; 71(8): 832–841.
  43. Briguori C, Sarais C, Pagnotta P, et al. In-stent restenosis in small coronary arteries: impact of strut thickness. J Am Coll Cardiol. 2002; 40(3): 403–409.
  44. Brugaletta S, Sabate M. Percutaneous treatment of extremely small coronary vessels: does size matter in terms of performance? JACC Cardiovasc Interv. 2017; 10(14): 1389–1391.
  45. Rathore S. Small coronary vessel angioplasty: outcomes and technical considerations. Vasc Health Risk Manag. 2010; 6: 915–922.
  46. Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation. 2005; 111(25): 3435–3442.
  47. Ellis SG, Popma JJ, Lasala JM, et al. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: analysis from the TAXUS-IV trial. J Am Coll Cardiol. 2005; 45(8): 1193–1200.
  48. Elezi S, Dibra A, Mehilli J, et al. Vessel size and outcome after coronary drug-eluting stent placement. J Am Coll Cardiol. 2006; 48(7): 1304–1309.
  49. Schampaert E, Cohen EA, Schlüter M, et al. C-SIRIUS Investigators. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol. 2004; 43(6): 1110–1115.
  50. Siontis GCM, Piccolo R, Praz F, et al. Percutaneous coronary interventions for the treatment of stenoses in small coronary arteries: a network meta-analysis. JACC Cardiovasc Interv. 2016; 9(13): 1324–1334.
  51. Kastrati A, Dirschinger J, Boekstegers P, et al. Influence of stent design on 1-year outcome after coronary stent placement: A randomized comparison of five stent types in 1,147 unselected patients. Catheter Cardiovasc Interv. 2000; 50(3): 290–297, doi: 10.1002/1522-726x(200007)50:3<290::aid-ccd5>3.0.co;2-w.
  52. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results. Circulation. 2001; 103(23): 2816–2821.
  53. Cassese S, Byrne RA, Tada T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart. 2014; 100(2): 153–159.
  54. Turco MA, Ormiston JA, Popma JJ, et al. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS program. JACC Cardiovasc Interv. 2008; 1(6): 699–709.
  55. Lee JZ, Singh N, Ortega G, et al. Composite outcomes in 2.25-mm drug eluting stents: a systematic review. Cardiovasc Revasc Med. 2015; 16(4): 237–242.
  56. Tam CC, Chan K, Lam S, et al. One-year clinical outcomes of patients implanted with a Resolute Onyx™ zotarolimus-eluting stent. J Int Med Res. 2018; 46(1): 457–463.
  57. Nestelberger T, Kaiser C, Jeger R. Drug-coated balloons in cardiovascular disease: benefits, challenges, and clinical applications. Expert Opin Drug Deliv. 2020; 17(2): 201–211.
  58. Mohiaddin H, Wong TD, Burke-Gaffney A, et al. Drug-Coated balloon-only percutaneous coronary intervention for the treatment of de novo coronary artery disease: a systematic review. Cardiol Ther. 2018; 7(2): 127–149.
  59. Kleber FX, Rittger H, Bonaventura K, et al. Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group. Clin Res Cardiol. 2013; 102(11): 785–797.
  60. Alfonso F, Scheller B. State of the art: balloon catheter technologies - drug-coated balloon. EuroIntervention. 2017; 13(6): 680–695.
  61. Kufner S, Cassese S, Valeskini M, et al. ISAR-DESIRE 3 Investigators. Long-Term efficacy and safety of paclitaxel-eluting balloon for the treatment of drug-eluting stent restenosis: 3-year results of a randomized controlled trial. JACC Cardiovasc Interv. 2015; 8(7): 877–884.
  62. Richelsen RK, Overvad TF, Jensen SE. Drug-Eluting balloons in the treatment of coronary de novo lesions: a comprehensive review. Cardiol Ther. 2016; 5(2): 133–160.
  63. Latib A, Colombo A, Castriota F, et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels. J Am Coll Cardiol. 2012; 60(24): 2473–2480.
  64. Giannini F, Latib A, Ancona MB, et al. A propensity score matched comparative study between paclitaxel-coated balloon and everolimus-eluting stents for the treatment of small coronary vessels. Catheter Cardiovasc Interv. 2017; 90(3): 380–386.
  65. Sinaga DA, Ho HH, Watson TJ, et al. Drug-Coated balloons: a safe and effective alternative to drug-eluting stents in small vessel coronary artery disease. J Interv Cardiol. 2016; 29(5): 454–460.
  66. Tian J, Tang Yd, Qiao S, et al. RESTORE SVD China Investigators. Two-year follow-up of a randomized multicenter study comparing a drug-coated balloon with a drug-eluting stent in native small coronary vessels: The RESTORE Small Vessel Disease China trial. Catheter Cardiovasc Interv. 2020; 95 Suppl 1: 587–597.
  67. Silverio A, Buccheri S, Venetsanos D, et al. Percutaneous treatment and outcomes of small coronary vessels. JACC: Cardiovascular Interventions. 2020; 13(7): 793–804.
  68. Megaly M, Rofael M, Saad M, et al. Outcomes with drug-coated balloons for treating the side branch of coronary bifurcation lesions. J Invasive Cardiol. 2018; 30(11): 393–399.
  69. Masiero G, Mojoli M, Ueshima D, et al. Current concepts on coronary revascularization using BRS in patients with diabetes and small vessels disease. J Thorac Dis. 2017; 9(Suppl 9): S940–S949.
  70. Mahmoud AN, Barakat AF, Elgendy AY, et al. Long-Term efficacy and safety of everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomized trials. Circ Cardiovasc Interv. 2017; 10(5).
  71. Stiehm M, Wüstenhagen C, Siewert S, et al. Impact of strut dimensions and vessel caliber on thrombosis risk of bioresorbable scaffolds using hemodynamic metrics. Biomed Tech (Berl). 2019; 64(3): 251–262.
  72. Wiebe J, Baquet M, Dörr O, et al. Long-term follow-up and predictors of target lesion failure after implantation of everolimus-eluting bioresorbable scaffolds in real-world practice. Int J Cardiol. 2020; 312: 42–47.
  73. Hideo-Kajita A, Garcia-Garcia H, Kolm P, et al. Comparison of clinical outcomes between Magmaris and Orsiro drug eluting stent at 12 months: Pooled patient level analysis from BIOSOLVE II–III and BIOFLOW II trials. Int J Cardiol. 2020; 300: 60–65.
  74. Serruys PW, Farooq V, Vranckx P, et al. A global risk approach to identify patients with left main or 3-vessel disease who could safely and efficaciously be treated with percutaneous coronary intervention: the SYNTAX Trial at 3 years. JACC Cardiovasc Interv. 2012; 5(6): 606–617.
  75. O'Connor NJ, Morton JR, Birkmeyer JD, et al. Effect of coronary artery diameter in patients undergoing coronary bypass surgery. Northern New England Cardiovascular Disease Study Group. Circulation. 1996; 93(4): 652–655.
  76. Rodriguez A, Rodríguez Alemparte M, Fernández Pereira C, et al. LASMAL investigators. Latin American randomized trial of balloon angioplasty vs coronary stenting for small vessels (LASMAL): immediate and long-term results. Am J Med. 2005; 118(7): 743–751.
  77. Schofer J, Schlüter M, Gershlick AH, et al. E-SIRIUS Investigators. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet. 2003; 362(9390): 1093–1099.
  78. Mehilli J, Dibra A, Kastrati A, et al. Intracoronary Drug-Eluting Stenting to Abrogate Restenosis in Small Arteries (ISAR-SMART 3) Study Investigators. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J. 2006; 27(3): 260–266.
  79. Cortese B, Micheli A, Picchi A, et al. Paclitaxel-coated balloon versus drug-eluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart. 2010; 96(16): 1291–1296.
  80. Sim HW, Ananthakrishna R, Chan SP, et al. Treatment of very small de novo coronary artery disease with 2.0 mm drug-coated balloons showed 1-year clinical outcome comparable with 2.0 mm drug-eluting stents. J Invasive Cardiol. 2018; 30(7): 256–261.
  81. Nishiyama N, Komatsu T, Kuroyanagi T, et al. Clinical value of drug-coated balloon angioplasty for de novo lesions in patients with coronary artery disease. Int J Cardiol. 2016; 222: 113–118.
  82. Funatsu A, Nakamura S, Inoue N, et al. A multicenter randomized comparison of paclitaxel-coated balloon with plain balloon angioplasty in patients with small vessel disease. Clin Res Cardiol. 2017; 106(10): 824–832.
  83. Her AeY, Ann SH, Singh GB, et al. Comparison of paclitaxel-coated balloon treatment and plain old balloon angioplasty for de novo coronary lesions. Yonsei Med J. 2016; 57(2): 337–341.
  84. Shin ES, Ann SH, Balbir Singh G, et al. Fractional flow reserve-guided paclitaxel-coated balloon treatment for de novo coronary lesions. Catheter Cardiovasc Interv. 2016; 88(2): 193–200.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl